Long COVID can affect brain function for years after infection

While the Phase II portion of the study evaluating AN2’s epetraborole met the primary endpoint, it failed in a “key” secondary endpoint prompting trial termination.

First, HER2. Now, HER3. That’s the plan of at­tack for BioN­Tech in its ap­par­ent bid to fol­low in the foot­steps of an­ti­body-drug con­ju­gate leader Dai­ichi